drugset / Trial / NCT02354612

Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

NCT02354612 ↗

Expanded access No longer available Tracon Pharmaceuticals Inc.

Summary

Open-label, continuation study

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Carotuximab Monoclonal antibody — —
Background Axitinib Small molecule — —
Background Bevacizumab Monoclonal antibody — —
Background Capecitabine Small molecule — —
Background Pazopanib Small molecule — —

Indications